Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cinoxacin (Cinobac, Eli Lilly & Co.).

D R Guay

    Drug Intelligence & Clinical Pharmacy
    |December 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Cinoxacin is an antibacterial drug for urinary tract infections (UTIs). Its role compared to first-line agents is uncertain, but it may be valuable for prostatitis and UTI prophylaxis.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Review of cefditoren, an advanced-generation, broad-spectrum oral cephalosporin.

    Clinical therapeutics·2002
    Same author

    Adjunctive agents in the management of chronic pain.

    Pharmacotherapy·2001
    Same author

    Pet-assisted therapy in the nursing home setting: potential for zoonosis.

    American journal of infection control·2001
    Same author

    Pharmacokinetics and tolerability of extended-release clarithromycin.

    Clinical therapeutics·2001
    Same author

    An update on the role of nitrofurans in the management of urinary tract infections.

    Drugs·2001
    Same author

    Pharmacodynamics and pharmacokinetics of cefdinir, an oral extended spectrum cephalosporin.

    The Pediatric infectious disease journal·2001

    Area of Science:

    • Pharmacology
    • Infectious Diseases
    • Urology

    Background:

    • Cinoxacin is a synthetic organic acid antibacterial agent.
    • It is structurally related to nalidixic and oxolinic acid.
    • Approved for treating urinary tract infections (UTIs) caused by susceptible gram-negative microorganisms.

    Purpose of the Study:

    • To evaluate the role of cinoxacin in treating UTIs compared to first-line agents.
    • To assess cinoxacin's efficacy in pyelonephritis treatment.
    • To explore potential uses in prostatitis and recurrent UTI prophylaxis.

    Main Methods:

    • Comparison of cinoxacin with established first-line UTI treatments.
    • Limited patient numbers in pyelonephritis efficacy studies.
    • Cost analysis of cinoxacin versus alternative agents.

    Related Experiment Videos

    Main Results:

    • Uncertainty regarding cinoxacin's role in routine UTI treatment.
    • Limited data on efficacy in pyelonephritis.
    • Cinoxacin is more expensive than current first-line agents.

    Conclusions:

    • Cinoxacin may be valuable for prostatitis and recurrent UTI prophylaxis, requiring further study.
    • Reserve cinoxacin for UTIs caused by resistant organisms or treatment failures.
    • Cinoxacin could potentially replace nalidixic acid in the future.